WO2024214062 - MITO-ESCULETIN FOR THE TREATMENT OF NAFLD AND NASH
National phase entry is expected:
Publication Number
WO/2024/214062
Publication Date
17.10.2024
International Application No.
PCT/IB2024/053607
International Filing Date
12.04.2024
Title **
[English]
MITO-ESCULETIN FOR THE TREATMENT OF NAFLD AND NASH
[French]
MITO-ESCULÉTINE POUR LE TRAITEMENT DE LA NAFLD ET DE LA NASH
Applicants **
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
Anusandhan Bhawan, 2 Rafi Marg
New Delhi, Delhi 110001, IN
Inventors
KOTAMRAJU, Srigiridhar
CSIR-Indian Institute of Chemical
Technology, Tarnaka
Hyderabad, Telangana 500007, IN
SINGURU, Gajalakshmi
CSIR-Indian Institute of Chemical
Technology, Tarnaka
Hyderabad, Telangana 500007, IN
PULIPAKA, Sriravali
CSIR-Indian Institute of Chemical
Technology, Tarnaka
Hyderabad, Telangana 500007, IN
SHAIKH, Altab
CSIR-Indian Institute of Chemical
Technology, Tarnaka
Hyderabad, Telangana 500007, IN
ANDUGULAPATI, Balaji Sai
CSIR-Indian Institute of Chemical
Technology, Tarnaka
Hyderabad, Telangana 500007, IN
THENNATI, Rajamannar
Sun Pharma Advanced Research Centre
Sun Pharma Road, Nima Compound
Vadodara, Gujurat 390012, IN
CHEMPON, Hridya
CSIR-Indian Institute of Chemical
Technology, Tarnaka
Hyderabad, Telangana 500007, IN
Priority Data
202311026984
12.04.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1859 | |
| EPO | Filing, Examination | 10685 | |
| Japan | Filing | 530 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6435 |
Total: 20084 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to 6,7-dihydroxy coumarin phosphonium amphiphile compounds for use in the treatment of fatty liver diseases. Preferably, wherein the fatty liver 5 disease is selected from one or more conditions from the group of, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fibrosis, Weber-Christian disease, Wolman's disease, acute fatty liver of pregnancy, and lip dystrophy, adipose tissue hypertrophy. The present invention also relates to compositions containing a compound of Formula I, II or III and a pharmaceutically acceptable excipient.[French]
La présente invention concerne des composés amphiphiles de 6,7-dihydroxy coumarine phosphonium destinés à être utilisés dans le traitement de stéatoses hépatiques. De préférence, la stéatose hépatique est choisie parmi une ou plusieurs affections du groupe comprenant la stéatose hépatique non alcoolique (NAFLD), la stéatohépatite non alcoolique (NASH), la fibrose, la maladie de Weber-Christian, la maladie de Wolman, la stéatose hépatique aiguë de la grossesse, la lipodystrophie et l'hypertrophie des tissus adipeux. La présente invention concerne également des compositions contenant un composé de formule I, II ou III et un excipient pharmaceutiquement acceptable.